🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ayer se entregaron los premios fundación y queremos dar la enhorabuena a todos los premiados, en especial a nuestros compañeros del servicio de Oncología Médica, Cristina, Vega, Pablo y Clara 🏆 Seguimos avanzando por una investigación de excelencia 🔬 fihguv.es/acto-de-entreg…

¡Estamos de enhorabuena!🎉 Ayer recogimos una de las ayudas de investigación del Grupo Español de Cáncer de Pulmón para el proyecto IMPULSO liderado por la Dra. Espinosa 🧬🚀 🔬 Exploramos respuesta a inmunoterapia mediante ctDNA y patrones de metilación en CPNM mutado en KRAS. FIHGUV HOSPITAL GENERAL

📌 Congratulations to Dr. Paula Espinosa and Excelencia Oncología Molecular for being awarded by SLCG for their groundbreaking project focused on lung cancer patients. 🧬🫁 #LungCancerResearch #MolecularOncology #CancerInnovation FIHGUV CIBERONC Ester Munera Silvia Calabuig

📢We are pleased to announce that Prof. Eloisa Jantus is the Vice President-Elect of International Society of Liquid Biopsy 🧬ISLB is the leading international company in education and research on the clinical implementation of LB Congratulations to ELO Visit more at islb.info

🔥 ctDNA Testing: Smoke Detector vs. Fire Investigation! 🔥 Nice analogy by Alex Wyatt 🧬🧬🧬Not all ctDNA tests serve the same purpose! Some detect cancer early (like a smoke detector), while others characterizetumor properties to guide treatment (like a fire

🚨 Announcing the 2025-2029 ISLB Executive Committee! 🌍🩸 We are pleased to announce the newly elected ISLB Executive Committee for the term November 2025 – November 2029:

🚨 ctDNA as a Prognostic Biomarker in Esophagogastric Cancer 🧬🩸 🔍 Key Findings from Lander et al., 2024: ✅ Postoperative ctDNA detection predicts recurrence risk 📊 ✅ Patients with ctDNA+ in MRD window had 6.2x higher recurrence risk ⚠️ ✅ 100% recurrence rate in ctDNA+

🔬 The ESMO Tumor-Agnostic Classifier and Screener (ETAC-S) introduces a framework for evaluating molecularly guided therapies beyond tumor type. 💡 Where does Liquid Biopsy fit in? ✅ Enables non-invasive genomic profiling for tumor-agnostic therapies 🩸 ✅ Detects targetable

🔝 Miriam Lobo, de #OncologíaMédica del HOSPITAL GENERAL, acreditada como profesional médico de excelencia en #CáncerHereditario por la SEOM 👉 La consulta de Consejo Genético valora unos 100 pacientes al año con sospecha de este síndrome hereditario 📎 acortar.link/V9QnHj

Survey Participation Request on Behalf of International Society of Liquid Biopsy & OncoAlert Oncologist Attitudes and Practices on Liquid Biopsy 👉 buff.ly/4kgngY6 This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your

🩸 Genomic Characterization of Metastatic Patterns in Prostate Cancer using ctDNA🧬 🔍 Key Insights from the SCRUM-Japan MONSTAR SCREEN project: ✅ ctDNA analysis identified genomic alterations linked to synchronous & metachronous metastases. ✅ MYC, APC, BRCA2, and DNA

Congratulations to Susana Torres Martínez for receiving the 1st GIDO award for lung cancer research projects! 🏆🧬 A truly well-deserved recognition!!! #LungCancerResearch Excelencia Oncología Molecular Ester Munera

Our colleague Susana Torres Martínez receiving the 1st GIDO award yesterday! Congratulations Susana for your work and effort! Let's do science!🚀🧬🔬 #sciencematter

Reminder!!🚨 Join us tomorrow at 16:00 PM for another edition of Coding Lung Cancer: EGFR. Don’t miss the latest insights on EGFR-mutant NSCLC! Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ Juan Carlos Laguna Cristina Teixidó, Drs Martin Lazaro, Ana Callejo & Jose A. López #LungCancer #EGFR #Oncology Hospital Clínic

📍Nuestra tradicional comida de Fallas del Laboratorio de Oncología Molecular. Disfrutando de la mejor compañía!!! 🍰🥟⁦Excelencia Oncología Molecular⁩ ⁦Ester Munera⁩ ⁦silvia calabuig⁩ ⁦FIHGUV⁩

🩸🎉Thrilled to share that the Journal of Liquid Biopsy is now officially live in PubMed and PMC! This milestone marks a significant step forward for the journal, and we extend our congratulations to everyone who contributed to this achievement. Check it out here:

Discussing Multicancer early detection tests and liquid biopsies during the MATOS Breast conference with @MCristofanill Hope Rugo Mark Pegram Joyce Oshaughnessey Edgardo Santos, MD, FACP, FASCO International Society of Liquid Biopsy The Medical Educator Consortium Cristofanilli CTC Laboratory

🚨 New Perspective on ctDNA in NSCLC: Understanding Acquired Resistance 🧬🩸 📖 NatureRevClinOncol , 2025 🔬 This expert review outlines how circulating tumor DNA (ctDNA) is reshaping the detection of acquired resistance to targeted therapies in metastatic NSCLC. 🔍 Key

📢 #ESMOFellowship applications are now open! The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch or #ClinicalResearch projects. 📅 Apply by: 29 May 2025 🔗 ow.ly/tz3e50VAQuM Evandro de Azambuja, MD, PhD Teresa Amaral, MD, PhD

🚨 Liquid Biopsy at Baseline Adds Prognostic & Predictive Value in mCRC 🧬🩸 From the FIRE-4 (AIO-KRK-0114) Study — Stintzing et al., Journal of Clinical Oncology 2025 🔍 Key Highlights: ✅ 13% of RASwt patients by tissue were RASmut on liquid biopsy (LB) ✅ RASmut and BRAFV600E mutations